Börse:
0,889€
2,79%
Echtzeit-Aktienkurs Sophiris Bio
Bid:
0,840€
Ask:
0,938€
| Allgemeine Informationen | ||
|---|---|---|
| Börsenwert: | 26,86 Mio. EUR (30,21 Mio. x 0,889€) | |
| Website: | - | |
| Sektor: | Medizin / Biotechnologie | |
| News-Radar | |
|---|---|
| dpa-AFX Pro - | Newsbot - |
| dpa-AFX - | Reuters - |
| 2016 | 2017 | 2018 | |
|---|---|---|---|
| KUV | - | - | - |
| KGV | - | - | - |
| Div. Rend. | - | - | - |
Echtzeit-Chart der Sophiris Bio Aktie
Börsenkurse Sophiris Bio
| Dollar Indikation | 0,955$ | 0 | 1,004$ | 0 | 0,979$ | -1,07% |
| Euro Indikation | 0,872€ | 0 | 0,916€ | 0 | 0,894€ | -2,96% |
| Börse Stuttgart | 0,840€ | 3500 | 0,938€ | 3500 | 0,889€ | 2,79% |
| Tradegate | 0,872€ | 3444 | 0,916€ | 3277 | 0,894€ | 0,64% |
| Lang & Schwarz | 0,861€ | 58045 | 0,906€ | 55206 | 0,884€ | -0,37% |
Fundamentaldaten der Sophiris Bio Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2018 | 0,00 Mio. | -6,78 Mio. | -6,78 Mio. | -0,23 | 0,00% | - | - |
| 2017 | 0,00 Mio. | -8,63 Mio. | -8,63 Mio. | -0,29 | 0,00% | - | - |
| 2016 | 0,00 Mio. | -11,16 Mio. | -11,16 Mio. | -0,49 | 0,00% | - | - |
Profil der Sophiris Bio Aktie
Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which develops products for the treatment of urological diseases. It is currently developing PRX302 as a treatment for the symptoms of benign prostatic hyperplasia which is a non cancerous enlargement of the prostate gland that causes a restriction in urine flow from the urethra resulting in lower urinary tract symptoms. The company was founded in May 2003 and is headquartered in La Jolla, CA.
TraderFox GmbH:
Impressum & Datenschutz -
Allgemeine Geschäftsbedingungen